Nasdaq to delist company run by drug price gouger Shkreli

Martin Shkreli, center, leaves the courthouse after his arraignment in New York, Thursday, Dec. 17, 2015. Shkreli, the former hedge fund manager vilified in nearly every corner of America for buying a pharmaceutical company and jacking up the price of a life-saving drug more than fiftyfold, was arrested Thursday on securities fraud charges unrelated to the furor. (AP Photo/Seth Wenig)

TRENTON, N.J. (AP) — One of the biotech companies run by Martin Shkreli, the reviled drug price-gouger charged with securities fraud last week, was informed Wednesday that its stock will be delisted by Nasdaq because of Shkreli’s arrest and other issues.

Meanwhile, KaloBios Pharmaceuticals Inc. also is dealing with the abrupt resignation of its accounting firm and a void left by its firing of Shkreli.

KaloBios was running out of money and planning to suspend its research programs and shut down operations in November. That’s when Shkreli, the CEO of Turing Pharmaceuticals Inc., swooped in and gained controlling interest of KaloBios stock. Shkreli was immediately named chief executive officer and chairman of the board of the South San Francisco, California, drug developer.

In a statement Wednesday, KaloBios said that Nasdaq wrote that it will be removed from trading on Dec. 30 if KaloBios doesn’t appeal. The company has not yet decided whether it will appeal.

Nasdaq cited reasons for the delisting including the indictment and arrest of both Shkreli and an outside attorney for KaloBios, Evan Greebel, plus the company’s noncompliance with Nasdaq financial reporting rules. KaloBios has not filed with the U.S. Securities and Exchange Commission a report on its financial results for the three months ended Sept. 30, as publicly traded companies are required to do every three months.

Shkreli became notorious after hiking the price of Daraprim, the only approved drug for toxoplasmosis, a rare and sometimes deadly parasitic infection, by 5,000 percent — from $13.50 to $750 per pill. Shkreli has been deluged with criticism from patients, politicians and others since hiking Daraprim’s price late in the summer, shortly after the U.S. rights to sell it were bought by Turing, a biotech company Shkreli founded last year.

Last Thursday, Shkreli, a 32-year-old former hedge fund manager, was arrested in New York and charged with securities fraud and conspiracy related to a pharmaceutical company he previously ran called Retrophin. Federal prosecutors allege that from 2009 to 2014, Shkreli made bad trades that lost money of some investors in his hedge fund, MSMB Capital Management. Prosecutors say he then looted Retrophin for $11 million to pay back his disgruntled clients.

Shkreli has pleaded not guilty and said that he was targeted for increasing Daraprim’s price. He was released on $5 million bail Thursday. Greebel was charged with conspiracy and also pleaded not guilty. The two men face similar allegations in a civil complaint filed by the SEC.

KaloBios fired Shkreli as CEO and he resigned from its board on Thursday, though the company didn’t announce that until Monday. Also Monday, its independent registered public accounting firm, Marcum LLP, resigned as the independent accounting firm for KaloBios, less than two weeks after being retained on Dec. 8.

KaloBios has not announced who will serve as CEO and board chairman, and it hasn’t responded to questions on the subject by The Associated Press. Its stock hasn’t traded since last Wednesday, when shares closed at $23.59.

Shkreli resigned on Friday as CEO of Turing, which has offices in New York and Zug, Switzerland. provides commenting to allow for constructive discussion on the stories we cover. In order to comment here, you acknowledge you have read and agreed to our Terms of Service. Users who violate these terms, including use of vulgar language or racial slurs, will be banned. If you see an inappropriate comment, please flag it for our moderators to review.

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s